Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saul Genuth

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
Diabetes|October 27, 2005
Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetesSaul Genuth, Wanjie Sun, Patricia Cleary, et al.
Journal of Diabetes and Its Complications|November 17, 2012
The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetesVincent M Monnier, David R Sell, Christopher Strauch, et al.
Cardiovascular Diabetology|September 6, 2015
Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetesVincent M Monnier, Wanjie Sun, Xiaoyu Gao, et al.
Journal of Diabetes Research|June 25, 2015
Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2DJoel Zonszein, Manuel Lombardero, Faramarz Ismail-Beigi, et al.
Diabetes|November 23, 2013
Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributionsDavid M Nathan, Margaret Bayless, Patricia Cleary, et al.
Clinical Trials (London, England)|June 26, 2012
Evolution of the study coordinator role: the 28-year experience in Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC)Mary E Larkin, Gayle M Lorenzi, Meg Bayless, et al.
Archives of Internal Medicine|July 29, 2009
Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005), David M Nathan, Bernard Zinman, et al.
The New England Journal of Medicine|June 6, 2003
Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitusDavid M Nathan, John Lachin, Patricia Cleary, et al.
Cardiovascular Diabetology|February 12, 2016
Skin collagen fluorophore LW-1 versus skin fluorescence as markers for the long-term progression of subclinical macrovascular disease in type 1 diabetesDavid R Sell, Wanjie Sun, Xiaoyu Gao, et al.
Diabetes Care|November 3, 2016
Cardiovascular Autonomic Neuropathy and Cardiovascular Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) StudyRodica Pop-Busui, Barbara H Braffett, Bernie Zinman, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Diabetes|October 27, 2005
Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetesSaul Genuth, Wanjie Sun, Patricia Cleary, et al.
Journal of Diabetes and Its Complications|November 17, 2012
The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetesVincent M Monnier, David R Sell, Christopher Strauch, et al.
Cardiovascular Diabetology|September 6, 2015
Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetesVincent M Monnier, Wanjie Sun, Xiaoyu Gao, et al.
Journal of Diabetes Research|June 25, 2015
Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2DJoel Zonszein, Manuel Lombardero, Faramarz Ismail-Beigi, et al.
Diabetes|November 23, 2013
Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributionsDavid M Nathan, Margaret Bayless, Patricia Cleary, et al.
Clinical Trials (London, England)|June 26, 2012
Evolution of the study coordinator role: the 28-year experience in Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC)Mary E Larkin, Gayle M Lorenzi, Meg Bayless, et al.
Archives of Internal Medicine|July 29, 2009
Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005), David M Nathan, Bernard Zinman, et al.
The New England Journal of Medicine|June 6, 2003
Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitusDavid M Nathan, John Lachin, Patricia Cleary, et al.
Cardiovascular Diabetology|February 12, 2016
Skin collagen fluorophore LW-1 versus skin fluorescence as markers for the long-term progression of subclinical macrovascular disease in type 1 diabetesDavid R Sell, Wanjie Sun, Xiaoyu Gao, et al.
Diabetes Care|November 3, 2016
Cardiovascular Autonomic Neuropathy and Cardiovascular Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) StudyRodica Pop-Busui, Barbara H Braffett, Bernie Zinman, et al.
Pageof 6